1078 West Baltimore Pike
Media, PA 19063
(484) 227-4350
(484) 227-4677 fax
Most Recent Peer-reviewed Publications
- Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects.
- Higher Levels of c-Met Expression and Phosphorylation Identify Cell Lines With Increased Sensitivity to AMG-458, a Novel Selective c-Met Inhibitor With Radiosensitizing Effects
- Molecular profiling to optimize treatment in non-small cell lung cancer: A review of potential molecular targets for radiation therapy by the translational research program of the Radiation Therapy Oncology Group
- Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer
- Heat shock protein 90 inhibition: Rationale and clinical potential
Medical School
Shanghai Medical University, Peoples Republic of China - 1987
Residency
University of California School of Medicine
Fellowship
University of Rochester Medicine & Dentistry, NY
Board Certification
Radiation Oncology
Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Research and Clinical Interests
Dr. Bo Lu is a board-certified Radiation Oncologist who comes to Jefferson from Vanderbilt University in Nashville, Tenn., where he was an Ingram associate professor with tenure in the Department of Radiation Oncology and Cancer Biology of the University’s School of Medicine. He was also an attending radiation oncologist at the Vanderbilt University Medical Center, member of the Ingram Cancer Center, and director of the Translational Research Program and Lung Cancer Research Program. Dr. Lu received his Ph.D. in Cell and Molecular Biology from Baylor School of Medicine in Houston and his Doctorate in Medicine from Shanghai Medical University in China. Dr. Lu completed his residency in radiation oncology at the University of Southern California, School of Medicine. Dr. Lu’s focus is on radiation-induced cell death in lung patients, among other basic science areas. His clinical interests include the integration of novel targeted agents in the treatment of lung cancer, radiosurgery for lung cancer, and reduction of toxicities from thoracic radiation. More recently, Dr. Lu has looked at cancer stem cells for enhancing radiotherapy in a setting of lung cancer.